{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:18:30Z","timestamp":1790983110984,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01553-4","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T12:48:23Z","timestamp":1785588503000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pathological Complete Response in a Patient With HER2-Negative Esophagogastric Junction Cancer Undergoing Conversion-Intent Surgery After Ramucirumab Plus Paclitaxel Following Nivolumab-Based Chemotherapy: A Case Report"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0007-9583","authenticated-orcid":false,"given":"Yuki","family":"Yamasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaname","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunobu","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,1]]},"reference":[{"key":"1553_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomized, open-label, phase 3 trial. Lancet. 2021;398:27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"Lancet"},{"issue":"6","key":"1553_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102071","volume":"8","author":"Y Narita","year":"2023","unstructured":"Narita Y, Matsushima T, Sakamoto Y, Matsuoka H, Tanioka H, Kawakami T, et al. Chemotherapy after nivolumab for advanced gastric cancer (REVIVE): a prospective observational study. ESMO Open. 2023;8(6):102071. https:\/\/doi.org\/10.1016\/j.esmoop.2023.102071.","journal-title":"ESMO Open"},{"key":"1553_CR3","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.21873\/anticanres.14187","volume":"40","author":"K Kato","year":"2020","unstructured":"Kato K, Narita Y, Mitani S, Honda K, Masuishi T, Taniguchi H, et al. Efficacy of cytotoxic agents after progression on anti-PD-(L)1 antibody for pre-treated metastatic gastric cancer. Anticancer Res. 2020;40:2247\u201355. https:\/\/doi.org\/10.21873\/anticanres.14187.","journal-title":"Anticancer Res"},{"key":"1553_CR4","volume-title":"Japanese Classification of Gastric Carcinoma","author":"Japanese Gastric Cancer Association","year":"2017","unstructured":"Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma. 15th ed. Tokyo: Kanehara &\u3000Co.; 2017. Japanese.","edition":"15"},{"key":"1553_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ags3.12515","volume":"6","author":"K Yoshida","year":"2022","unstructured":"Yoshida K, Yasufuku I, Terashima M, Rha SY, Bae JM, Li G, et al. International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg. 2022;6:227\u201340. https:\/\/doi.org\/10.1002\/ags3.12515.","journal-title":"Ann Gastroenterol Surg"},{"key":"1553_CR6","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.21873\/anticanres.17583","volume":"45","author":"Y Hojo","year":"2025","unstructured":"Hojo Y, Tomita T, Igeta M, Murakami M, Kohno S, Nakao E, et al. Impact of nivolumab plus chemotherapy on conversion therapy in clinical stage IVB HER2-negative gastric cancer. Anticancer Res. 2025;45:2091\u2013102. https:\/\/doi.org\/10.21873\/anticanres.17583.","journal-title":"Anticancer Res"},{"issue":"1","key":"1553_CR7","doi-asserted-by":"publisher","first-page":"28841","DOI":"10.1038\/s41598-025-13714-9","volume":"15","author":"T Matsumoto","year":"2025","unstructured":"Matsumoto T, Ikoma T, Makiyama C, Yasuda T, Boku S, Nakasya A, et al. Efficacy and safety of taxane plus ramucirumab for advanced gastric cancer after chemotherapy plus nivolumab. Sci Rep. 2025;15:28841. https:\/\/doi.org\/10.1038\/s41598-025-13714-9.","journal-title":"Sci Rep"},{"key":"1553_CR8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3892\/mco.2022.2537","volume":"16","author":"T Nose","year":"2022","unstructured":"Nose T, Funakoshi Y, Suto H, Nagatani Y, Imamura Y, Toyoda M, et al. Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge. Mol Clin Oncol. 2022;16:104. https:\/\/doi.org\/10.3892\/mco.2022.2537.","journal-title":"Mol Clin Oncol"},{"key":"1553_CR9","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1159\/000502415","volume":"12","author":"H Maki","year":"2019","unstructured":"Maki H, Yuasa Y, Fujiwara S, Fukuta M, Takeuchi T, Fujimoto K, et al. Unresectable advanced gastric cancer with skin invasion followed by total gastrectomy after second-line chemotherapy. Case Rep Oncol. 2019;12:671\u201380. https:\/\/doi.org\/10.1159\/000502415.","journal-title":"Case Rep Oncol"},{"key":"1553_CR10","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.21873\/invivo.12584","volume":"35","author":"T Namikawa","year":"2021","unstructured":"Namikawa T, Marui A, Yokota K, Fujieda Y, Munekage M, Uemura S, et al. Successful conversion surgery for advanced gastric cancer with multiple liver metastases following ramucirumab plus paclitaxel combination treatment. In Vivo. 2021;35:2929\u201335. https:\/\/doi.org\/10.21873\/invivo.12584.","journal-title":"In Vivo"},{"key":"1553_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40792-022-01412-x","volume":"8","author":"K Fukuda","year":"2022","unstructured":"Fukuda K, Arigami T, Tokuda K, Yanagita S, Matsushita D, Kawasaki Y, et al. Successful conversion surgery for stage IV gastric cancer with liver metastases after second-line chemotherapy with ramucirumab and paclitaxel: a case report. Surg Case Rep. 2022;8:58. https:\/\/doi.org\/10.1186\/s40792-022-01412-x.","journal-title":"Surg Case Rep"},{"key":"1553_CR12","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s12893-021-01390-1","volume":"21","author":"Z Saze","year":"2021","unstructured":"Saze Z, Kase K, Nakano H, Yamauchi N, Kaneta A, Watanabe Y, et al. Functional benefits of the double flap technique after proximal gastrectomy for gastric cancer. BMC Surg. 2021;21:392. https:\/\/doi.org\/10.1186\/s12893-021-01390-1.","journal-title":"BMC Surg"},{"key":"1553_CR13","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3760\/cma.j.cn112139-20220418-00175","volume":"60","author":"L Yang","year":"2022","unstructured":"Yang L, Wu JZ, You J, Fan L, Jing CQ, Wang Q, et al. A multicenter retrospective study on the efficacy of different anti-reflux reconstruction methods after proximal gastrectomy for gastric cancer. Zhonghua wai ke za zhi [Chinese journal of surgery]. 2022;60:838\u201345. https:\/\/doi.org\/10.3760\/cma.j.cn112139-20220418-00175.","journal-title":"Zhonghua wai ke za zhi [Chinese journal of surgery]"},{"key":"1553_CR14","doi-asserted-by":"publisher","first-page":"5243","DOI":"10.1007\/s00464-021-08902-3","volume":"36","author":"B Yu","year":"2022","unstructured":"Yu B, Park KB, Park JY, Lee SS, Kwon OK, Chung HY, et al. Double tract reconstruction versus double flap technique: short-term clinical outcomes after laparoscopic proximal gastrectomy for early gastric cancer. Surg Endosc. 2022;36:5243\u201356. https:\/\/doi.org\/10.1007\/s00464-021-08902-3.","journal-title":"Surg Endosc"},{"key":"1553_CR15","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.asjsur.2022.04.110","volume":"46","author":"E Nishimura","year":"2023","unstructured":"Nishimura E, Irino T, Matsuda S, Fukuda K, Nakamura R, Kawakubo H, et al. Comparison of changes in body-fat mass and reflux esophagitis among reconstruction methods for proximal gastrectomy. Asian J Surg. 2023;46:394\u20138. https:\/\/doi.org\/10.1016\/j.asjsur.2022.04.110.","journal-title":"Asian J Surg"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01553-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01553-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01553-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T12:48:26Z","timestamp":1785588506000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01553-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1553"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01553-4","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"assertion":[{"value":"23 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. Ethical approval was waived for this case report by the institutional review board of our institution.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication was obtained from the patient for publication of this case report and accompanying images.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y.Ya. has received honoraria from Bristol Myers Squibb. All other authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"175"}}